In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a ...
Qure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical ...
Swedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether ...
AstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab ...
Danish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 ...
Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on ...
The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: ...
Sweden’s Nanexa has granted Novo Nordisk a global license to use its PharmaShell drug delivery technology in up to five ...
Aptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene ...
Swiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate ...
Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped ...
Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results